Breaking News Instant updates and real-time market news.

ATVI

Activision Blizzard

$46.78

0.26 (0.56%)

, BMY

Bristol-Myers

$52.63

0.61 (1.17%)

10:33
12/06/18
12/06
10:33
12/06/18
10:33

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Activision Blizzard (ATVI) upgraded to Overweight from Neutral at JPMorgan with analyst Alexia Quadrani saying the stock is down 45% from an all-time high in early October, and now trades at 16.5 times forward consensus earnings, compared to 25.5 times and 23.0 times on average over the prior one and three year periods. 2. Bristol-Myers (BMY) upgraded to Outperform from Market Perform at BMO Capital with analyst Alex Arfaei saying the risk-reward on the stock at current price "seems attractive." 3. Hostess Brands (TWNK) upgraded to Overweight from Neutral at JPMorgan analyst Ken Goldman saying by this time next year, today's two major headwinds - lost business with Walmart (WMT) and the "EBITDA-hemorrhaging" Cloverhill acquisition - will be lapped and potentially become tailwinds. 4. Spirit Airlines (SAVE) upgraded to Outperform from Neutral at with analyst Jose Caiado De Sousa saying after a "massive" Q4 unit revenue guidance boost last week, the analyst sees further upside in the equity into H1 of 2019, with expected continued momentum in non-ticket revenue production amid a lower oil environment and a benign competitive backdrop. 5. Synopsys (SNPS) upgraded to Buy from Hold at Benchmark with analyst Gary Mobley citing slightly better than expected Q4 results and in-line FY19 guidance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ATVI

Activision Blizzard

$46.78

0.26 (0.56%)

BMY

Bristol-Myers

$52.63

0.61 (1.17%)

TWNK

Hostess Brands

$11.70

0.41 (3.63%)

SAVE

Spirit Airlines

$62.82

-0.31 (-0.49%)

SNPS

Synopsys

$89.86

0.455 (0.51%)

  • 13

    Dec

  • 29

    Dec

  • 24

    Jan

  • 20

    May

ATVI Activision Blizzard
$46.78

0.26 (0.56%)

12/06/18
JPMS
12/06/18
UPGRADE
Target $66
JPMS
Overweight
Activision Blizzard upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Alexia Quadrani upgraded Activision Blizzard to Overweight while lowering her price target for the shares to $66 from $72. The stock is down 45% from an all-time high in early October, and now trades at 16.5 times forward consensus earnings, compared to 25.5 times and 23.0 times on average over the prior one and three year periods, Quadrani tells investors in a research note. The analyst thinks investors are now overly focused on short term execution and growth, creating an attractive entry point "for what remains a compelling long-term story driven by a secular shift to digital, extension of core IP to mobile, an expanding console and player base and continued innovation in live services." She also believes the current valuation gives Activision little credit for options such as King advertising, Esports expansion and revenue growth, or new mobile titles.
12/04/18
MSCO
12/04/18
NO CHANGE
Target $150
MSCO
Overweight
Take-Two stands to benefit from Steam price cut, says Morgan Stanley
Morgan Stanley analyst Brian Nowak noted that Valve announced last week it was changing the take rate on its Steam PC-game distribution platform, reducing Steam's take rate to 20% from 30% on all sales over $50M per game. For any game that has achieved scale on Steam, this 10% increase to gross revenue will "effectively fall directly to the game's operating profit," said Nowak. He expects the impact to be minimal for Activision Blizzard (ATVI) and Electronic Arts (EA), who distribute most or all of their games through wholly-owned platforms, but said that for Take-Two (TTWO) the impact could be more significant. The lower platform fees could drive as much as 8% upside to his FY20 EPS estimate for Take-Two, noted Nowak, who maintains an Overweight rating and $150 price target on its shares.
12/04/18
GABE
12/04/18
INITIATION
Target $62
GABE
Buy
Activision Blizzard initiated with a Buy at Gabelli
Gabelli analyst Alec Boccanfuso initiated Activision Blizzard with a Buy and a $62 price target. The analyst said Activision continues to innovate and is best positioned to benefit from the growth of eSports, mobile gaming, the digital revenue shift and the rise of the Chinese games market.
12/04/18
12/04/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Activision Blizzard (ATVI) initiated with a Buy at Gabelli. 2. Kratos Defense (KTOS) initiated with an Outperform at Baird. 3. Capital Product (CPLP) initiated with a Buy at B. Riley FBR. 4. Veeva (VEEV) initiated with an Outperform at Leerink. 5. Presidio (PSDO) initiated with a Buy at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
BMY Bristol-Myers
$52.63

0.61 (1.17%)

12/02/18
PIPR
12/02/18
NO CHANGE
Target $12
PIPR
Overweight
Alpine Immune Sciences' ALPN-101 active in GvHD, CTA by YE18, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes that Alpine (ALPN) presented two posters at ASH on proprietary variable Immunoglobulin Domain technology. In vivo data at ASH showed single doses enhanced survival in GvHD models compared to Bristol Myer's (BMY) Nujolix, he notes, adding that a CTA for ALPN-101 by YE18 should enable healthy volunteer data and lead to a Phase II GvHD start next year. The analyst also points out that Alpine presented novel Transmembrane ImmuneModulatory Proteins that can be engineered into T cells to enhance response in immunosuppressive environments. Importantly these strategies differ from TIP technology partnered to Kite (GILD) and offer further partnering opportunity, Tenthoff contends. He reiterates an Overweight rating and $12 price target on Alpine's shares.
12/06/18
JPMS
12/06/18
NO CHANGE
Target $70
JPMS
Overweight
JPMorgan still sees path to substantial Opdivo growth despite Bristol's setbacks
JPMorgan analyst Chris Schott said that investors are clearly concerned about Opdivo growth following several recent setbacks for Bristol-Myers, including mixed TMB data, pending RCC competition, and a failed SCLC study, but he still sees a path to substantial growth for the drug based on the numerous important readouts in both lung and non-lung indications coming in the next 12 months. Meanwhile, his analysis suggests Bristol-Myers' share price reflects little, if any, Opdivo growth from current levels. Given his view, and its convergence with what he believes to be the consensus view, on Opdivo, Schott sees the long term risk/reward for Bristol shares as highly attractive and keeps an Overweight rating on the stock with a $70 price target.
12/06/18
BMOC
12/06/18
UPGRADE
BMOC
Outperform
Bristol-Myers upgraded to Outperform from Market Perform at BMO Capital
12/06/18
BMOC
12/06/18
UPGRADE
Target $60
BMOC
Outperform
Bristol-Myers upgraded to Outperform at BMO Capital on better Opdivo sales
As reported earlier, BMO Capital analyst Alex Arfaei upgraded Bristol-Myers to Outperform from Market Perform and raised his price target to $60 from $56, saying the risk-reward on the stock at current price "seems attractive". The analyst notes that a number of R&D setbacks have reduced expectations for the company's immuno-oncology franchise, raising his forecasts on Opdivo to reflect the "low" street consensus. Arfaei adds that the Street is modeling flattish gross margins, but his forecast calls for a 2% improvement by 2021 with Opdivo revenue expectations coming about 10%-15% above consensus. The analyst also raises his FY19 EPS view to $4.18 from $3.93 to reflect the more optimistic Opdivo targets.
TWNK Hostess Brands
$11.70

0.41 (3.63%)

09/26/18
SBSH
09/26/18
INITIATION
Target $13
SBSH
Neutral
Hostess Brands initiated with a Neutral at Citi
Citi analyst Alexis Borden started Hostess Brands (TWNK) with a Neutral rating and $13 price target. The analyst sees a "host of questions" over Hostess' near-to-medium term outlook due to the recent revenue headwinds from lost Walmart (WMT) display space, heightened cost inflation pressures and continued "sluggish" Sweet Baked Goods category growth. As such, Borden is cautious on the shares near-term.
09/26/18
09/26/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. First Cash Financial (FCFS) initiated with an Overweight at Barclays. 2. Hostess Brands (TWNK) initiated with a Neutral at Citi. 3. Repligen (RGEN) initiated with a Neutral at H.C. Wainwright. 4. Evofem (EVFM) initiated with an Overweight at Cantor Fitzgerald. 5. Elanco (ELAN) initiated with a Market Perform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/01/18
SPHN
10/01/18
NO CHANGE
Target $15
SPHN
Overweight
Hostess' CEO re-bases earnings to 'achiveable' level for FY18, says Stephens
Stephens analyst Farha Aslam reiterated an Overweight rating and $15 price target on Hostess Brands, telling investors in a research note that shares have been weak given challenging market conditions in the baked sweet goods category and losses related to the new Cloverhill bakery. Aslam expects the baked sweet goods category to remain competitive, but acknowledges that new CEO Andy Callahan has re-based earnings to a level that is likely achievable in fiscal 2018. She views the turnaround at the Cloverhill bakery as a significant earnings driver and a meaningful long-term positive
12/06/18
JPMS
12/06/18
UPGRADE
Target $14
JPMS
Overweight
Hostess Brands upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Ken Goldman upgraded Hostess Brands (TWNK) to Overweight and raised his price target for the shares to $14 from $13. By this time next year, today's two major headwinds - lost business with Walmart (WMT) and the "EBITDA-hemorrhaging" Cloverhill acquisition - will be lapped and potentially become tailwinds, Goldman tells investors in a research note. The analyst, however, does not yet recommend the Hostess shares for investors with shorter-term horizons as he suspects that the Walmart turnaround is taking longer than management anticipated. Nonetheless, he thinks the stock's risk/reward over the next 12-plus months is favorable.
SAVE Spirit Airlines
$62.82

-0.31 (-0.49%)

11/28/18
11/28/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Spirit Airlines (SAVE) upgraded to Overweight from Neutral at JPMorgan with analyst Jamie Baker saying he admits to being "clearly misgauged" over the elasticity of Spirit's passenger base following the company's Q4 TRASM outlook "surprise." 2. Ooma (OOMA) upgraded to Outperform from Market Perform at William Blair with analyst Bhavan Suri saying the "solid" quarter shows Ooma's "consistent execution." 3. DaVita (DVA) upgraded to Outperform from Market Perform at Raymond James with analyst John Ransom saying the stock has fallen about 18% since the company reported a Q3 earnings miss and since the defeat of the California ballot initiative, creating an attractive entry point. 4. Aspen Technology (AZPN) upgraded to Buy from Hold at Canaccord with analyst David Hynes citing valuation. 5. Union Pacific (UNP) upgraded to Buy from Hold at Deutsche Bank with analyst Amit Mehrotra saying after several years of "weak" cost control, Union Pacific is now positioned for at least $3B in profit improvement. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/28/18
JPMS
11/28/18
UPGRADE
Target $82
JPMS
Overweight
JPMorgan says Spirit Airlines 'equity ascent' not over, upgrades to Overweight
JPMorgan analyst Jamie Baker upgraded Spirit Airlines to Overweight from Neutral and raised his price target for the shares to $82 from $59. The analyst admits to being "clearly misgauged" over the elasticity of Spirit's passenger base following the company's Q4 TRASM outlook "surprise." After marking for fuel, Baker believes Spirit is likely to earn somewhere between $6.80 and $8.60 in earnings per share for 2019. In 2020, the analyst "can envision" $7.85 to $9.90 per share. Based on these 2020 "goal posts," he arrives at fair value for the stock between $82 and $104 per share, "implying still-healthy potential upside despite yesterday's rally." As such, Baker does not believe Spirit's "equity ascent has concluded."
12/06/18
FBCO
12/06/18
UPGRADE
Target $77
FBCO
Outperform
Spirit Airlines upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Jose Caiado De Sousa upgraded Spirit Airlines to Outperform from Neutral and raised his price target on the shares to $77 from $59. Following a "massive" Q4 unit revenue guidance boost last week, the analyst sees further upside in the equity into H1 of 2019, with expected continued momentum in non-ticket revenue production amid a lower oil environment and a benign competitive backdrop. The company appears to be an "underappreciated" RASM story as it continues to execute well, with plenty of company-specific ancillary initiatives as it unleashes the value of its technology investments, he contends.
11/28/18
JPMS
11/28/18
UPGRADE
Target $82
JPMS
Overweight
Spirit Airlines upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Jamie Baker upgraded Spirit Airlines to Overweight and raised his price target for the shares to $82 from $59.
SNPS Synopsys
$89.86

0.455 (0.51%)

12/06/18
12/06/18
UPGRADE
Target $110

Buy
Synopsys upgraded to Buy after 'ultra conservative' FY19 guidance at Benchmark
As previously reported, Benchmark analyst Gary Mobley upgraded Synopsys to Buy from Hold after the company reported slightly better than expected Q4 results and in-line FY19 guidance. He cites the recent share price decline ahead of the report, what he sees as a "high likelihood" that Synopsys will continue to experience high-single-digit percentage organic revenue growth and management's renewed focus to drive operating margins higher. Mobley, who also contends that management's FY19 revenue guidance will "prove ultra conservative," set a $110 price target on Synopsys shares.
12/06/18
BNCH
12/06/18
UPGRADE
BNCH
Buy
Synopsys upgraded to Buy from Hold at Benchmark
12/06/18
NEED
12/06/18
NO CHANGE
Target $115
NEED
Buy
Synopsys price target raised to $115 from $105 at Needham
Needham analyst Richard Valera raised his price target on Synopsys to $115 and kept his Buy rating after its "solid" Q4 results and in-line initial FY19 guidance. The analyst points to "healthy design-driven demand for its tools despite macro turbulence" along with a raise by the company's "historically conservative management" for its long-term earnings growth from high single digit % to double-digits and a long-term revenue growth target of high single digits. Valera adds that the new targets are "supported by a healthier long term outlook for core Electronic Design Automation segment, as well as momentum and critical mass in the company's IP and SI businesses."
11/27/18
DADA
11/27/18
NO CHANGE
Target $110
DADA
Buy
Synopsys 'underlying business activity remains robust', says DA Davidson
DA Davidson analyst Thomas Diffely kept his Buy rating and $110 price target on Synopsys ahead of its Q4 results next week, saying investors should expect a "record quarter" as the company's underlying business activity remains "robust". The analyst believes that the "elevated level of chip design activity and ever increasing chip complexity" will drive the electronic design automation industry to new heights. However, Diffely also expects the management to take a conservative stance on guidance and call for more modest sequential earnings growth amid "increased trade war chatter and slowing smartphone demand in recent months".

TODAY'S FREE FLY STORIES

CBSH

Commerce Bancshares

$61.42

0.09 (0.15%)

13:02
09/16/19
09/16
13:02
09/16/19
13:02
Initiation
Commerce Bancshares initiated  »

Commerce Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

WMS

Advanced Drainage

$33.09

0.86 (2.67%)

, ITCI

Intra-Cellular

$9.99

0.05 (0.50%)

13:02
09/16/19
09/16
13:02
09/16/19
13:02
On The Fly
Fly Insider: Advanced Drainage, Merit among week's notable insider trades »

Welcome to "Fly Insider,"…

WMS

Advanced Drainage

$33.09

0.86 (2.67%)

ITCI

Intra-Cellular

$9.99

0.05 (0.50%)

LAND

Gladstone Land

$12.00

0.0745 (0.62%)

PRU

Prudential

$88.52

-1.33 (-1.48%)

ACHC

Acadia

$32.37

0.385 (1.20%)

ZAYO

Zayo Group

$33.82

(0.00%)

AMPH

Amphastar

$21.79

0.27 (1.25%)

PH

Parker-Hannifin

$178.30

-3.89 (-2.14%)

MMSI

Merit Medical

$27.74

0.09 (0.33%)

FCNCA

First Citizens

$481.53

1.58 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Sep

  • 27

    Sep

  • 01

    Oct

  • 10

    Oct

  • 05

    Nov

  • 27

    Dec

XLF

Financial Select Sector

$28.26

-0.24 (-0.84%)

13:00
09/16/19
09/16
13:00
09/16/19
13:00
Options
Put spread swap in Financial Sector ETF totals 160K contracts »

Put spread swap in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMBF

UMB Financial

$66.71

-0.25 (-0.37%)

13:00
09/16/19
09/16
13:00
09/16/19
13:00
Initiation
UMB Financial initiated  »

UMB Financial assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

CL

Colgate-Palmolive

$69.11

-1.57 (-2.22%)

12:55
09/16/19
09/16
12:55
09/16/19
12:55
Options
Colgate Palmolive put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 01

    Nov

CHD

Church & Dwight

$71.77

-0.25 (-0.35%)

12:53
09/16/19
09/16
12:53
09/16/19
12:53
Hot Stocks
Church & Dwight CEO buys 7,000 shares »

Church & Dwight…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

  • 06

    Nov

ED

Consolidated Edison

$89.88

0.05 (0.06%)

12:51
09/16/19
09/16
12:51
09/16/19
12:51
Hot Stocks
Con Edison challenges repeal of Clean Power Plan »

Con Edison, as part of a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Nov

IBOC

International Bancshares

$39.74

0.165 (0.42%)

12:50
09/16/19
09/16
12:50
09/16/19
12:50
Hot Stocks
International Bancshares increases dividend 10% to 55c per share »

International Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COMM

CommScope

$13.11

1.02 (8.44%)

12:46
09/16/19
09/16
12:46
09/16/19
12:46
Hot Stocks
CommScope reports FCC approves spectrum access system for deployment »

CommScope announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

12:45
09/16/19
09/16
12:45
09/16/19
12:45
General news
FOMC Checklist: »

FOMC Checklist: The FOMC…

OMVKY

OMV AG

$0.00

(0.00%)

12:41
09/16/19
09/16
12:41
09/16/19
12:41
Initiation
OMV AG initiated  »

OMV AG resumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$291.23

-2.77 (-0.94%)

, SNE

Sony

$59.78

-0.59 (-0.98%)

12:40
09/16/19
09/16
12:40
09/16/19
12:40
Periodicals
Netflix lands global streaming rights to 'Seinfeld,' L.A. Times reports »

Netflix (NFLX) has struck…

NFLX

Netflix

$291.23

-2.77 (-0.94%)

SNE

Sony

$59.78

-0.59 (-0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

  • 16

    Oct

WPX

WPX Energy

$12.10

1.12 (10.20%)

12:40
09/16/19
09/16
12:40
09/16/19
12:40
Options
10% rise in shares prompts ratio roll up in WPX Energy »

10% rise in shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

E

Eni SpA

$31.43

0.42 (1.35%)

12:39
09/16/19
09/16
12:39
09/16/19
12:39
Initiation
Eni SpA initiated  »

Eni SpA resumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$10.40

-0.12 (-1.14%)

12:35
09/16/19
09/16
12:35
09/16/19
12:35
Options
Bed Bath & Beyond put volume heavy and directionally bearish »

Bearish flow noted in Bed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$216.86

-3.13 (-1.42%)

12:33
09/16/19
09/16
12:33
09/16/19
12:33
Periodicals
Goldman Sachs chief risk officer Vince to retire at end of year, Reuters says »

Goldman Sachs said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

  • 15

    Oct

BA

Boeing

$379.03

-0.84 (-0.22%)

12:32
09/16/19
09/16
12:32
09/16/19
12:32
Hot Stocks
Boeing to sell Inventory Locator Service to Hearst's CAMP Systems »

Boeing has signed an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

LMT

Lockheed Martin

$390.15

5.43 (1.41%)

12:27
09/16/19
09/16
12:27
09/16/19
12:27
Periodicals
Greg Ulmer to temporarily run Lockheed aeronautics division, Reuters reports »

Greg Ulmer, head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRC

California Resources

$14.85

3.03 (25.63%)

12:25
09/16/19
09/16
12:25
09/16/19
12:25
Options
California Resources call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICAD

iCAD

$7.09

0.19 (2.75%)

12:25
09/16/19
09/16
12:25
09/16/19
12:25
Conference/Events
iCAD to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

  • 12

    Nov

CNHI

CNH Industrial

$11.19

-0.01 (-0.09%)

12:21
09/16/19
09/16
12:21
09/16/19
12:21
Periodicals
Elliott builds stake in CNH, sees value in breakup, Bloomberg reports »

Paul Singer's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHE

Chemed

$421.82

0.32 (0.08%)

12:19
09/16/19
09/16
12:19
09/16/19
12:19
Hot Stocks
Chemed subsidiary acquires franchise operater for $120M »

Roto-Rooter Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 19

    Nov

  • 20

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
09/16/19
09/16
12:17
09/16/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
09/16/19
09/16
12:16
09/16/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADNT

Adient

$24.79

-0.32 (-1.27%)

12:15
09/16/19
09/16
12:15
09/16/19
12:15
Options
Adient put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.